ORBSEN THERAPEUTICS LIMITED

Their core work

Orbsen Therapeutics is an Irish biotechnology SME specializing in mesenchymal stromal cell (MSC) therapies for chronic diseases, particularly kidney disease. They develop allogeneic cell-based treatments and have been involved in clinical-stage programs (Phase 1b/2a) targeting diabetic kidney disease and end-stage renal disease. Beyond their therapeutic pipeline, they contribute to advances in scalable, automated stem cell manufacturing processes and biomaterial-based delivery systems for cell therapies.

What they specialise in

How they've shifted over time

All three of Orbsen's H2020 projects started within a tight 2015-2016 window, reflecting a concentrated burst of EU-funded activity rather than a long evolution. Their early work centered on clinical-stage MSC therapy for kidney disease (NEPHSTROM), while simultaneously branching into manufacturing automation (AUTOSTEM) and biomaterial delivery for neurology (BrainMatTrain). There is no recent-period keyword data, indicating the company did not take on new H2020 projects after 2016 — their trajectory beyond this period is not visible in the CORDIS record.

Orbsen's H2020 participation ended by 2016; any recent direction would need to be confirmed through other sources, though their trajectory pointed toward clinical translation and manufacturing scale-up of cell therapies.

How they like to work

Orbsen participated exclusively as a partner, never leading a consortium — consistent with its role as a specialist SME contributing proprietary cell therapy expertise to larger research groups. With 25 unique partners across 10 countries from just 3 projects, they operated within large, multi-national consortia. This suggests they are a sought-after niche contributor rather than a consortium organizer.

Through 3 projects, Orbsen built a network of 25 partners spanning 10 countries — a broad European footprint for a small company. Their network likely includes academic medical centers, cell manufacturing specialists, and clinical research organizations across Western Europe.

What sets them apart

Orbsen occupies a rare niche as an SME with clinical-stage allogeneic MSC therapy programs, bridging the gap between academic stem cell research and industrial-scale therapeutic manufacturing. Their simultaneous involvement in clinical trials (NEPHSTROM), manufacturing automation (AUTOSTEM), and delivery systems (BrainMatTrain) shows they understand the full chain from cell production to patient treatment. For consortium builders, they bring proprietary MSC technology plus real clinical development experience — not just lab-stage research.

Highlights from their portfolio

• NEPHSTROM
  Clinical-stage (Phase 1b/2a) cell therapy trial for diabetic kidney disease — rare for an SME to be involved in human clinical testing within an EU consortium.
• AUTOSTEM
  Largest EC funding (EUR 448,375) and addresses a critical bottleneck — scalable automated manufacturing of therapeutic stem cells.
• BrainMatTrain
  An MSCA training network extending Orbsen's cell therapy expertise into neurology and biomaterial delivery, broadening their disease area reach.